SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

30 May 2025 Evaluate
The total revenue for the quarter ended March 2025 remained nearly unchanged at Rs. 2481.96 millions.Net Profit recorded in the quarter ended March 2025 rise to 29.52% to Rs. 206.23  millions  compared to R. 159.23 millions in corresponding previous quarter.Operating profit for the quarter ended March 2025 rose to 427.70 millions as compared to 351.33 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 2481.96 2457.98 0.98 7827.48 7092.63 10.36 7827.48 7092.63 10.36
Other Income 14.24 16.46 -13.49 62.24 44.60 39.55 62.24 44.60 39.55
PBIDT 427.70 351.33 21.74 1461.98 1213.04 20.52 1461.98 1213.04 20.52
Interest 50.65 56.09 -9.70 185.41 234.57 -20.96 185.41 234.57 -20.96
PBDT 377.05 295.24 27.71 1276.57 978.47 30.47 1276.57 978.47 30.47
Depreciation 86.40 79.16 9.15 343.37 315.16 8.95 343.37 315.16 8.95
PBT 290.65 216.08 34.51 933.20 663.31 40.69 933.20 663.31 40.69
TAX 84.42 56.85 48.50 249.39 169.07 47.51 249.39 169.07 47.51
Deferred Tax 37.92 10.55 259.43 52.99 17.79 197.86 52.99 17.79 197.86
PAT 206.23 159.23 29.52 683.81 494.24 38.36 683.81 494.24 38.36
Equity 88.65 84.65 4.73 88.65 84.65 4.73 88.65 84.65 4.73
PBIDTM(%) 17.23 14.29 20.56 18.68 17.10 9.21 18.68 17.10 9.21

SMS Pharmaceuticals Share Price

396.55 -19.20 (-4.62%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×